William Rosellini

will

William Rosellini is the President of CytoImmune Therapeutics, Inc, a clinical stage biotechnology company. Also, a serial life science entrepreneur, breaking down what worked and what didn't.

Regulation D Rule 507

Section 230.507 – Disqualifying provision relating to exemptions under §§230.504 and 230.506. (a) No exemption under §230.504 or §230.506 shall be available for an issuer if such issuer, any of its predecessors or affiliates have been subject to any order, judgment, or decree of any court of competent jurisdiction temporarily, preliminary or permanently enjoining such

Regulation D Rule 507 Read More »

Regulation D

Regulation D Private Securities Offerings Under the federal securities laws, any offer or sale of a security must either be registered with the SEC or meet an exemption. Regulation D under the Securities Act provides a number of exemptions from the registration requirements, allowing some companies to offer and sell their securities without having to

Regulation D Read More »